Comparative Effectiveness and Tolerability of Topical Capsaicin Versus Pregabalin in Chemotherapy-Induced Peripheral Neuropathy: A Prospective Observational Study
DOI:
https://doi.org/10.52206/jsmc.2026.16.1.1113Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and debilitating complication of neurotoxic chemotherapy, significantly affecting quality of life and treatment adherence in cancer patients. Pharmacological management remains challenging, with limited efficacy and tolerability of commonly used systemic agents.
Objective: To compare the effectiveness and safety of topical capsaicin and oral pregabalin in patients with CIPN receiving neurotoxic chemotherapy.
Methodology: This prospective, observational comparative study was conducted from January to December 2023 at the Clinical Oncology Department of Swat Institute of Nuclear Medicine Oncology and Radiotherapy, Pakistan. A total of 117 patients who developed new-onset CIPN during or after chemotherapy were included. Patients received either topical capsaicin 0.075% (Group-A, n = 77) or oral pregabalin (Group-B, n = 40). Symptom improvement was assessed at two and six weeks. Adverse events, treatment compliance, and discontinuation rates were also recorded. Statistical analysis included chi-square tests, independent t-tests, and logistic regression adjusted for chemotherapy regimen.
Results: Both groups demonstrated symptom improvement; however, response rates were significantly higher in the capsaicin group at both two weeks (85.7% vs. 32.5%, p = 0.005) and six weeks (93.5% vs. 32.5%, p = 0.001). Logistic regression confirmed superior efficacy of capsaicin [OR 6.2; 95% CI 2.8–13.5]. No systemic adverse events were reported with capsaicin, whereas pregabalin was associated with dizziness, edema, and sleepiness, leading to high treatment discontinuation.
Conclusion: Topical capsaicin demonstrated superior efficacy and better tolerability compared with pregabalin in the management of CIPN. These findings suggest that topical capsaicin may represent a safer and more effective alternative for symptomatic relief in patients receiving neurotoxic chemotherapy.
Keywords: Antineoplastic Agents, Capsaicin, Neuralgia, Peripheral Nervous System Diseases, Pregabalin.
References
Alessandri-Haber N, Dina OA, Yeh JJ, Parada CA, Reichling DB, Levine JD. Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat. J. Neurosci. 2004;24(18):4444-4452. https://doi.org/10.1523/JNEUROSCI.0242-04.2004
Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RV. Technological advancements in cancer diagnostics: Improvements and limitations. Cancer Rep. 2023;6(2):e1764. https://doi.org/10.1002/cnr2.1764
Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9:20503121211034366. https://doi.org/10.1177/20503121211034366
Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022;10(4):1367-1401. https://doi.org/10.1016/j.gendis.2022.02.007
Abbas Z, Rehman S. An overview of cancer treatment modalities. Neoplasm. 2018;1:139-57. https://doi.org/10.5772/intechopen.76558
Fadel DM, Kamal Y, Hassouna AH, Ali A. Prevalence of oral side effects associated with chemo and radiotherapy in head and neck cancer treatment: a cross-sectional study in Egypt. OOR. 2024;10:100177. https://doi.org/10.1016/j.oor.2024.100177
Tao Z, Chen Z, Zeng X, Cui J, Quan M. An emerging aspect of cancer neuroscience: A literature review on chemotherapy-induced peripheral neuropathy. Cancer Lett. 2024:217433. https://doi.org/10.1016/j.canlet.2024.217433
Maihöfner C, Diel I, Tesch H, Quandel T, Baron R. Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. SCC. 2021;29(8):4223-4238. https://doi.org/10.1007/s00520-021-06042-x
Finsterer J, Löscher WN, Wanschitz J, Iglseder S. Orphan Peripheral Neuropathies. J Neuromuscul Dis. 2021;8(1):1-23. https://doi.org/10.3233/JND-200518
Jones D, Zhao F, Brell J, Lewis MA, Loprinzi CL, Weiss M, et al. Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J Cancer Surviv. 2015;9:1-10. https://doi.org/10.1007/s11764-014-0379-x
Yamamoto S, Egashira N. Drug repositioning for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a mechanism-and screening-based strategy. Front. Pharmacol. 2021;11:607780. https://doi.org/10.3389/fphar.2020.607780
Desforges AD, Hebert CM, Spence AL, Reid B, Dhaibar HA, Cruz-Topete D, et al. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update. Biomed Pharmacother. 2022;147:112671. https://doi.org/10.1016/j.biopha.2022.112671
Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, et al. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer. 2021;21(1):1319. https://doi.org/10.1186/s12885-021-09069-9
Atreya S. Pregabalin in Chemotherapy Induced Neuropathic Pain. Indian J Palliat Care. 2016;22(1):101-103. https://doi.org/10.4103/0973-1075.173941
van Haren FGAM, Steegers MAH, Cornelissen PHJM, Vissers KCP, van den Heuvel SAS. The Effect of Topical Capsaicin 8% on Pain in Chemotherapy-induced Peripheral Neuropathy. Pain Manag Nurs. 2025;26(2):e201-e206. https://doi.org/10.1016/j.pmn.2024.10.021
Lux MP, Flöther L, Frömter C, Rack B, Veselinovic K, Heine M, et al. Topical treatment of chemotherapy-induced peripheral neuropathy (CIPN) with high-concentration (179 mg) capsaicin patch in breast cancer patients - results of the QUCIP study. Front Oncol. 2024;14:1452099. https://doi.org/10.3389/fonc.2024.1452099
Casale R. Capsaicin 179-mg cutaneous patch in the treatment of post-surgical neuropathic pain: a scoping review of current evidence and place in therapy. Expert Rev Neurother. 2021;21(10):1147-1158. https://doi.org/10.1080/14737175.2021.1974842
Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325-3348. https://doi.org/10.1200/JCO.20.01399
Filipczak-Bryniarska I, Krzyzewski RM, Kucharz J, Michalowska-Kaczmarczyk A, Kleja J, Woron J, et al. High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience. Med Oncol. 2017;34(9):162. https://doi.org/10.1007/s12032-017-1015-1
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
